125 related articles for article (PubMed ID: 17970511)
1. Taking a subq approach to EPO: experience in the clinic.
Wish J
Nephrol News Issues; 2007 Oct; 21(11):68. PubMed ID: 17970511
[No Abstract] [Full Text] [Related]
2. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
[TBL] [Abstract][Full Text] [Related]
3. Understanding epoetin use: databases or clinical trials?
Roger SD
Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
[No Abstract] [Full Text] [Related]
4. [Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review].
Ranchon F; Hédoux S; Laville M; Fouque D; Decullier E; Chapuis F; Huot L
Nephrol Ther; 2010 Apr; 6(2):97-104. PubMed ID: 20097148
[TBL] [Abstract][Full Text] [Related]
5. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin claims monitoring policy: implications for clinical practice.
Messana T
Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
[TBL] [Abstract][Full Text] [Related]
7. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
[TBL] [Abstract][Full Text] [Related]
8. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
[TBL] [Abstract][Full Text] [Related]
9. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
10. The FDA black box for EPO: what should nephrologists do?
Singh AK
Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
[No Abstract] [Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
[TBL] [Abstract][Full Text] [Related]
13. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
[TBL] [Abstract][Full Text] [Related]
14. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
15. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
16. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
Wish JB
Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
18. The FDA, stocks, black boxes and ESAs.
Spry L
Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124
[No Abstract] [Full Text] [Related]
19. Reaction from renal associations. Renal Physicians Association.
Blaser R
Nephrol News Issues; 2007 May; 21(6):61-2, 64. PubMed ID: 17518126
[No Abstract] [Full Text] [Related]
20. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]